Quote:The Cornell study for patients with mild to moderate Alzheimer's disease is now about halfway enrolled. It is interesting, though extremely preliminary, to note that two patients who recently completed 12 weeks of dosing have themselves requested ongoing access to leronlimab due to their own subjective impression of clinical improvement. We are obviously eager to review the objective readout from this study, which will include an objective radiologic endpoint and should become available within four months of the last patient being enrolled. We are anxious to see enrollment continue and note that the study is open and the study team has been open to enrolling patients from outside the tri-state area.
So if they finish enrollment in two months, we should results in about six months from now, or April. This doesn't answer your question! But I'm excited about this trial. Any Alzheimer's result should be big news in a clinical setting where no one has a clue.